FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/Novo Nordisk Launches Phase 1 Study on Novel Peptide NNC0721-5186 for Weight Management
Zurück zur Forschungsbibliothek

Novo Nordisk Launches Phase 1 Study on Novel Peptide NNC0721-5186 for Weight Management

November 20, 2026
Share
Emergierende Forschung

Basiert auf emergierender Forschung. Diese Erkenntnisse sind versprechend, aber erfordern weitere Validierung.

Über diese Analyse

Diese Artikel sind eine AI-basierte Zusammenfassung eines kürzlich veröffentlichten Nachrichtenspieles oder einer klinischen Studienanzeige. Sie sind dazu gedacht, einen schnellen und zugänglichen Überblick für die Peptidforschungscommunity zu bieten. Für vollständige Genauigkeit empfehlen wir immer die unten angegebene Quelle zu überprüfen.

Novo Nordisk Launches Phase 1 Study on Novel Peptide NNC0721-5186 for Weight Management

Novo Nordisk A/S has initiated a new clinical trial to investigate the safety and efficacy of a novel peptide, NNC0721-5186, as a potential treatment for individuals living with overweight or obesity. This Phase 1 study aims to evaluate how the body processes this compound compared to both a placebo and semaglutide, an existing medication approved for weight management.

The importance of this research lies in its potential to provide new options for those struggling with obesity-related health issues. Peptide therapy has been gaining traction as a promising avenue for treating metabolic disorders, and NNC0721-5186 represents the latest addition to this field.

Background

Obesity is a major public health concern that affects millions of people worldwide. Current treatments often come with limitations or side effects, prompting researchers to explore new avenues like peptide therapy. Peptides are small proteins that can mimic hormones and influence various physiological processes in the body. They have shown promise in regulating appetite, metabolism, and insulin sensitivity.

Novo Nordisk's decision to study NNC0721-5186 underscores the company’s commitment to advancing treatments for obesity-related conditions. The trial will focus on understanding how this peptide interacts with the human body, which is crucial before moving forward into larger-scale clinical trials.

Key Details

The study, officially registered under ClinicalTrials.gov (NCT07940582), will recruit women who are living with overweight or obesity. Participants will be randomly assigned to receive either NNC0721-5186, semaglutide, or a placebo. The primary objective is to assess the safety profile of NNC0721-5186 and how it is absorbed, distributed, metabolized, and excreted by the body.

In addition to evaluating safety, researchers will also compare the pharmacokinetics (PK) of NNC0721-5186 with semaglutide in the first three dosing groups. This comparison will help establish a baseline for how this new peptide stacks up against an already approved medication used for weight management.

Key Takeaways

  • Novo Nordisk Aims to Advance Peptide Therapy: The study marks another step forward in Novo Nordisk's efforts to develop innovative treatments for obesity.
  • Safety and PK Evaluation: Researchers will focus on the safety profile and pharmacokinetics of NNC0721-5186, providing essential data for future clinical applications.
  • Comparison with Semaglutide: Initial phases of the study include a direct comparison between NNC0721-5186 and semaglutide to establish efficacy benchmarks.
  • Exclusive Focus on Women: The trial will initially recruit women only, allowing researchers to gather specific data relevant to this demographic.

What This Means

This research could pave the way for new treatment options in weight management. As peptide therapy continues to evolve, studies like these are crucial for understanding how novel peptides interact with the human body and compare against existing treatments. For the broader peptide community, Novo Nordisk's initiative highlights the ongoing importance of clinical trials in advancing therapeutic approaches.

---

Source: ClinicalTrials.gov — Published 2026-11-17

This article is for informational purposes only and does not constitute medical advice.

Bearbeitungsnotiz

Diese Analyse wurde mit AI-Tools generiert und durch den Peptide Contacts-Bearbeiterteam geprüft. Obwohl wir für die Genauigkeit streben, kann AI-generierter Inhalt Fehler oder Lücken enthalten. Wir ermutigen Leser, die ursprüngliche Quelle für vollständige Details, Methoden und Daten.

Peptide Contacts bietet vercurierte Forschungssummarien zur Informationszwecke an. Dieses Inhalte bilden keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Gesundheitsentscheidungen treffen.

Comments

Sign in to join the discussion

Dieser Artikel wurde mit AI generiert und kann ungenaue Informationen enthalten. Er wird zur Informationszwecke bereitgestellt und bildet keine medizinische Beratung aus. Stets überprüfen Sie die Information mit der ursprünglichen Quelle und beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Gesundheitsentscheidungen treffen.